The Role of Tuberin in Smooth Muscle Cell Proliferation

Summary

Principal Investigator: Geraldine Finlay
Abstract: DESCRIPTION (provided by applicant): This is an application for a Mentored Clinical Scientist Development Award for Dr. Geraldine Finlay to pursue research on the influence of tuberin on the control of smooth muscle cell growth in response to estrogen. Preliminary studies provide information that tuberin, the protein product of the TSC2 gene, is involved in regulating the growth response to estrogen and that MAP kinase is a vital signaling intermediate for this response. Further exploration of these observations will provide new insights into understanding the pathogenesis of diseases characterized by smooth muscle cell proliferation such as asthma, hypertension, atherosclerosis and lymphangioleiomyomatosis. Dr. Finlay will work in the laboratory of Dr. Barry Fanburg at the New England Medical Center, Tufts University School of medicine, who is an authority on smooth muscle biology and Dr David Kwiatkowski, a world expert in the genetics of TSC genes, at the Brigham and Women's Hospital, Harvard School of Medicine. Dr. Richard Karas, an expert in estrogen receptor cell signaling, at the New England Medical Center will also provide additional advisory support to Dr. Finlay. Facilities at each of the institutions will be readily available and participation in courses and conferences will be strongly encouraged. She will interact daily with Dr Fanburg and Dr. Kwiatkowski while spending time in each laboratory and will meet quarterly with an Advisory Committee. The proposed research will focus on the following specific aims: 1) To study the effects of tuberin on estrogen-mediated regulation of smooth muscle cell growth, 2)To assess the effects of tuberin on MAP kinase activation and MAP kinase function, 3)To investigate the effects of tuberin on the regulation of estrogen receptor function and 4) To study the effect of tuberin on estrogen-regulated vascular smooth muscle cell growth in vivo. These studies will allow Dr. Finlay to become educated and adept as a molecular biologist, give her the opportunity to complete and publish high quality research and to be competitive in acquiring a future independent research award while she assumes a staff position at this institution.
Funding Period: 2003-09-01 - 2009-08-31
more information: NIH RePORT

Top Publications

  1. ncbi Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin
    Geraldine A Finlay
    Pulmonary and Critical Care Division, Department of Medicine, Tupper Research Institute, New England Medical Center, Boston, Massacusetts 02111, USA
    Cancer Res 65:10881-90. 2005
  2. ncbi Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity
    Geraldine A Finlay
    Pulmonary and Critical Care Division, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Boston, MA 02111, USA
    Cancer Res 67:9878-86. 2007
  3. pmc Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
    Geraldine A Finlay
    Pulmonary and Critical Care Division, Tufts Medical Center, Boston, MA 02111, USA
    Mol Cancer Ther 8:1799-807. 2009

Scientific Experts

Detail Information

Publications3

  1. ncbi Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin
    Geraldine A Finlay
    Pulmonary and Critical Care Division, Department of Medicine, Tupper Research Institute, New England Medical Center, Boston, Massacusetts 02111, USA
    Cancer Res 65:10881-90. 2005
    ..Together, our data suggest that loss of tuberin, which causes mTOR activation, leads to a novel cellular growth-promoting pathway involving mitochondrial oxidant-dependent p42/44 MAPK activation and mitogenic growth responses to PDGF...
  2. ncbi Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity
    Geraldine A Finlay
    Pulmonary and Critical Care Division, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Boston, MA 02111, USA
    Cancer Res 67:9878-86. 2007
    ..Atorvastatin may have potential therapeutic benefit in TSC syndromes, including LAM...
  3. pmc Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
    Geraldine A Finlay
    Pulmonary and Critical Care Division, Tufts Medical Center, Boston, MA 02111, USA
    Mol Cancer Ther 8:1799-807. 2009
    ....